News

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

- Enrollment numbers rise to 239 in ongoing potentially pivotal study of Berubicin for treatment of GBM; Expected full enrollment…

1 year ago

StageZero Life Sciences, Ltd Announces Q3 2023 Financial Results and Operational Update

TORONTO, ON / ACCESSWIRE / November 15, 2023 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare…

1 year ago

Envision Pharma Group Announces New AI Innovation Board and Appoints Chairwoman

The new board and leadership appointment aligns with the company's commitment to advancing the industry through innovation and the expansion…

1 year ago

NanoViricides Has Filed its Quarterly Report – NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications

SHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed…

1 year ago

PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules

Filament Health and PharmAla Biotech also completed shipments to a number of Australian clientsVANCOUVER, British Columbia, Nov. 15, 2023 (GLOBE…

1 year ago

USDA-APHIS Determines that Yield10 Bioscience’s Stacked Herbicide Tolerant Camelina May Be Planted and Bred in the United States

-Herbicide Technology Critical to Enabling Large-Acreage Adoption of Camelina in North AmericaWOBURN, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience,…

1 year ago

USDA-APHIS Determines that Yield10 Bioscience’s Glufosinate Tolerant Camelina May Be Planted and Bred in the United States

-Yield10 Achieves a Significant Milestone in the Development of Camelina as a Commercial Crop for Producing Biofuels and Omega-3 Oils -On…

1 year ago

Shockwave Medical to Participate in the Piper Sandler 35th Annual Healthcare Conference

SANTA CLARA, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and…

1 year ago

Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes

– Randomized, placebo-controlled trial to assess 16-week treatment with CT-868 in participants with overweight or obesity with type 1 diabetes…

1 year ago

Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001

AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use DisorderToronto,…

1 year ago